Insider Cluster (3 insiders) ·Filed Sep 9, 2026

DNLI

Denali Therapeutics Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed22d 11h ago
Insider cluster: 3 insiders, $0.3M total
Actionable Insight • Neutral

Ignore this cluster — the dollar amounts are trivial relative to market cap and consistent with routine portfolio diversification. No insider buying to offset the sales. Monitor upcoming Phase 2/3 readouts for the real catalysts; insider trading patterns here are noise.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+5d
DNLI ▼ -7.00% at T+5d
NEUTRAL call ✗ call lost -7.00% · α vs SPY -6.34% · entry $21.57 → $20.06
Next anchor: T+20d in 4d
Latest observation: T+13 -0.23% FF3 residual α
Entry anchored
Sep 8, 04:00 PM ET
via 1-min bar
T+1d
-0.79%
call -0.79% · α -0.19%
$21.40
settled 23d ago
T+5d
-7.00%
call -7.00% · α -6.34%
$20.06
settled 17d ago
T+20d
—
call — · α —
—
in 4d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

Three Denali insiders (COFO, Director, CMO) sold a total of ~$349K in open-market sales over a 5-day window. The aggregate dollar value is ~0.01% of the $3.5B market cap, well below the 0.1% materiality threshold. These are routine, small-dollar sales by a mix of C-suite and board members — no single insider sold more than $250K. The cluster carries no informational signal and does not change the fundamental outlook for the stock.

Key Financial Metrics

Direction
selling
Total Value
$349.0K
Insiders
3

Key Facts

  • Three insiders sold shares totaling ~$349K over 5 days
  • Total sales represent ~0.01% of $3.5B market cap — trivial
  • Sales were open-market (code S), not tax-withholding or derivative exercises
  • Largest single sale was Director Thornberry's $247K; COFO Schuth sold $65K; CMO Chin sold $37K
  • No insider bought shares in the cluster window

Financial Impact

~$349K in insider sales, ~0.01% of market cap — immaterial

Risk Factors

  • Small insider sales could precede a broader sell-off if negative data emerges, but the amounts here are too small to signal informed selling
  • No insider buying to signal conviction ahead of catalysts

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (26 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-DNLI-1789027737969
12 reports for DNLI
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+60▲ +23.19%May 7, 2026
Filters
Rows
Reports for DNLI — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 2/10
$21.57 $20.06▼ −7.00%▼ −6.34%$20.00 (−7.28%)
Sep 4, 2026
27d ago
Insider Cluster
NEUTRAL ★ 2/10
$22.08 $20.38▼ −7.70%▼ −6.58%$20.00 (−9.42%)
Aug 6, 2026
8w ago
8-K
MIXED ★ 6/10
$24.83 $24.40▼ −1.73%▼ −2.13%$20.00 (−19.45%)
Jul 27, 2026
9w ago
Press Release
BEARISH ★ 6/10
$24.05 $23.15▲ +3.74%▲ +6.01%$20.00 (+16.84%)
Jun 18, 2026
15w ago
8-K
BULLISH ★ 6/10
$23.31 $24.73▲ +6.09%▲ +7.76%$20.00 (−14.20%)
Jun 18, 2026
15w ago
Press Release
BULLISH ★ 6/10
$23.31 $24.73▲ +6.09%▲ +7.76%$20.00 (−14.20%)
Jun 11, 2026
16w ago
Institutional Cluster
MIXED ★ 4/10
$21.02 $23.49▲ +11.75%▲ +11.32%$20.00 (−4.85%)
May 21, 2026
19w ago
Press Release
BEARISH ★ 7/10
$18.64 $20.41▼ −9.50%▼ −7.84%$20.00 (−7.30%)
May 7, 2026
21w ago
Press Release
BULLISH ★ 7/10
$19.62 $19.39▼ −1.17%▼ −2.64%$20.00 (+1.94%)
Apr 3, 2026
26w ago
8-K
NEUTRAL ★ 5/10
$19.38 $19.42▲ +0.21%▼ −3.93%$20.00 (+3.20%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Sep 10, 2026